Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Gains from Investment Securities (2021 - 2025)

Historic Gains from Investment Securities for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $60356.0.

  • InMed Pharmaceuticals' Gains from Investment Securities fell 6776.25% to $60356.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $60356.0, marking a year-over-year decrease of 6776.25%. This contributed to the annual value of $61410.0 for FY2025, which is 8210.66% up from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' Gains from Investment Securities is $60356.0, which was down 6776.25% from $61864.0 recorded in Q1 2025.
  • InMed Pharmaceuticals' 5-year Gains from Investment Securities high stood at $678475.0 for Q1 2024, and its period low was -$12307.0 during Q4 2022.
  • Over the past 5 years, InMed Pharmaceuticals' median Gains from Investment Securities value was $62140.0 (recorded in 2024), while the average stood at $153339.8.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 523272.93% in 2023, then crashed by 9088.19% in 2025.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Gains from Investment Securities stood at -$6030.0 in 2021, then plummeted by 104.1% to -$12307.0 in 2022, then soared by 5232.73% to $631685.0 in 2023, then plummeted by 90.12% to $62416.0 in 2024, then decreased by 3.3% to $60356.0 in 2025.
  • Its Gains from Investment Securities was $60356.0 in Q3 2025, compared to $61864.0 in Q1 2025 and $62416.0 in Q4 2024.